Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Liabilities

v3.22.4
Accrued Expenses and Other Liabilities
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2022 and 2021:

 

      2022       2021  
    As of December 31,  
    2022     2021  
Payroll and incentives   $ 1,705     $ 1,343  
Deferred revenue *     721       33  
General and administrative expenses     455       195  
Research and development expenses     130       381  
Other deferred liabilities **     88       899  
Total   $ 3,099     $ 2,851  

 

* At December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 is related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”). Both balances are expected to be recognized by March 31, 2023. At December 31, 2021, the balance of $33 was related to the Genentech Agreement. (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other research and Development Agreements).
** At December 31, 2022 and December 31, 2021, the balances of $88 and $899, respectively, related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements).